Conditions: Prostate Cancer
Keywords: Drug therapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1099
Healthy volunteers: no

Brief summary:
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Orteronel intervention 2: Prednisone intervention 3: Orteronel Placebo
Intervention descriptions: intervention 1: Orteronel tablets intervention 2: Prednisone tablets intervention 3: Orteronel placebo-matching tablets

Protocol document: